30 Jan 2019 17:28
For immediate release 30 January 2019
Evgen Pharma plc
("Evgen" or the "Company")
Grant of Options
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces that, on 28 January 2019, certain employees of the Company including the following Persons Discharging Managerial Responsibility ("PDMR") were granted nil cost options over a total of 826,743 ordinary shares in the Company exercisable, subject to the option vesting, for a period of up to ten years from the date of grant under the Evgen Pharma plc Long Term Incentive Plan ("LTIP").
PDMR | Position | Options granted |
Dr Stephen Franklin | Chief Executive Officer | 471,061
|
Richard Moulson | Chief Financial Officer | 155,682
|
Sally Ross | Clinical Development Officer | 200,000 |
The number of nil cost options awarded has been calculated by reference to the three month weighted average share price to 28 January 2018.
These nil cost options are subject to the rules of the LTIP. The options will vest on the third anniversary of grant subject to a minimum absolute total shareholder return (TSR) from the grant date to the vesting date of 10%, at which 25% of the awards will vest, and then on a straight line basis to a 20% TSR at which 100% of the awards will vest. Re-testing of this performance condition after the vesting date is not permitted.
Enquiries:
Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com
| c/o +44 (0) 20 7466 5000 |
finnCap Geoff Nash, Teddy Whiley (Corporate Finance) Alice Lane, Manasa Patil (ECM) www.finncap.com
| +44 (0) 20 7220 0500 |
WG Partners LLP Nigel Barnes, Claes Spång
| +44 (0) 20 3705 9330 |
Buchanan Mark Court, Sophie Wills, Tilly Abraham evgen@buchanan.uk.com
| +44 (0) 20 7466 5000 |
Notes for editors:
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Steve Franklin | |
2 | Reason for the notification | ||
a) | Position/status | Chief Executive | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Evgen Pharma Plc | |
b) | Legal Entity Identifier | 213800NO3E6TSTQO8K20
| |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Options over ordinary shares of 0.25 pence each GB00BSWYN304
| |
b) | Nature of the transaction | Grant of options | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
nil | 471,061 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
| |
f) | Date of the transaction | 28 January 2019 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Richard Moulson | |
2 | Reason for the notification | ||
a) | Position/status | Chief Financial Officer | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Evgen Pharma plc | |
b) | Legal Entity Identifier | 213800NO3E6TSTQO8K20
| |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Options over ordinary shares of 0.25 pence each
GB00BSWYN304
| |
b) | Nature of the transaction | Grant of options | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
nil | 155,682 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
| |
f) | Date of the transaction | 28 January 2019 | |
g) | Place of the transaction | London Stock Exchange, AIM | |
1 | Details of the person discharging managerial responsibilities/person closely associated | ||
a) | Name | Sally Ross | |
2 | Reason for the notification | ||
a) | Position/status | Clinical Development Officer | |
b) | Initial notification /Amendment | Initial Notification | |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
a) | Name | Evgen Pharma plc | |
b) | Legal Entity Identifier | 213800NO3E6TSTQO8K20
| |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
a) | Description of the financial instrument, type of instrument
Identification code | Options over ordinary shares of 0.25 pence each
GB00BSWYN304
| |
b) | Nature of the transaction | Grant of options | |
c) | Currency | GBP | |
d) | Price(s) and volume(s) | Price(s) | Volume(s) |
nil | 200,000 | ||
| |||
e) | Aggregated information - Aggregated volume - Price - Aggregated total |
| |
f) | Date of the transaction | 28 January 2019 | |
g) | Place of the transaction | London Stock Exchange, AIM | |